Safety, Tolerability and Effectiveness of Nuedexta in the Treatment of Pseudobulbar Affect (PBA)
A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 367 participants.
Also called NCT01799941
- Study
- In this atlas
Overview
- Design
- Interventional study; allocation not applicable; no masking; primary purpose treatment
- Phase
- Phase 4
- Enrolled
- 367 participants
- Sponsor
- Avanir Pharmaceuticals
- Registry
-
NCT01799941
-
- Other papers using this trial's data
- PRISM II: an open-label study to assess effectiveness of dextromethorphan/quinidine for pseudobulbar affect in patients with dementia, stroke or traumatic brain injury
- Safety, Tolerability, and Effectiveness of Dextromethorphan/Quinidine for Pseudobulbar Affect Among Study Participants With Traumatic Brain Injury: Results From the PRISM-II Open Label Study
- Start date
- (registry gives no type)
- Primary completion
- (actual)
- Completion
- (actual)
- Results first posted
- Countries
- United States
- Registry status
- Completed
Technical summary
Registry record NCT01799941. Allocation not applicable; no masking; primary purpose treatment. Start 2013-02 (registry gives no type); primary completion 2015-05 (actual). Results posted on 2017-03-15.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Safety, Tolerability and Effectiveness of Nuedexta in the Treatment of Pseudobulbar Affect (PBA)
- Acronym
- PRISM II
- Condition
- Pseudobulbar Affect (PBA)
- Condition
- Stroke
- Condition
- Dementia
- Condition
- Traumatic Brain Injury (TBI)
- Intervention (Drug)
- Nuedexta (DM 20 mg/Q 10 mg)
- Lead sponsor
- Avanir Pharmaceuticals
Record details
- Record id
cardio:ct-nct01799941- Content hash
d388a239ae4fc03d124052f2fd7bc40fa81386cb3254b0ca8ed7249a0dc18613